中英双方近日宣布，英国布里斯托大学孵化的AI生物科技初创公司CellVoyant成功筹集了760万英镑的种子资金。CellVoyant公司致力于利用人工智能成像技术，帮助干细胞疗法开发商更高效地研发新疗法。本轮融资由Octopus Ventures领投，Horizons Ventures、Air Street Capital和Verve Ventures参投。
CellVoyant的的核心技术是通过人工智能成像技术，对干细胞疗法的研究和开发提供实时、精准的监测。这一创新技术有望改变当前干细胞疗法开发过程中的瓶颈问题，提高研发效率，为患者带来更优质的疗法。
本次筹集的资金将主要用于进一步优化技术，扩大团队规模，以及推进与干细胞疗法开发商的合作。公司创始人兼CEO Tom Rowley表示：“我们非常高兴能获得这笔投资，这将帮助我们推动技术创新，为干细胞疗法开发商提供强有力的支持。”
英文翻译：
News Title: AI Biotech Company CellVoyant Raises £7.6 Million in Seed Funding
Keywords: Artificial Intelligence, Biotechnology, Stem Cell Therapy
News Content:
CellVoyant, an AI-driven biotech startup incubated by the University of Bristol, has recently raised £7.6 million in seed funding. The company aims to use artificial intelligence imaging technology to help stem cell therapy developers create new treatments more effectively. The round was led by Octopus Ventures, with participation from Horizons Ventures, Air Street Capital, and Verve Ventures.
CellVoyant’s core technology employs AI imaging to provide real-time, precise monitoring for stem cell therapy research and development. This innovative approach has the potential to address bottlenecks in the current stem cell therapy development process, improving efficiency and delivering better treatments for patients.
The raised funds will be used to further optimize the technology, expand the team, and advance collaborations with stem cell therapy developers. Tom Rowley, CEO and founder of CellVoyant, said: “We are thrilled to receive this investment, which will enable us to drive technological innovation and provide strong support for stem cell therapy developers.
【来源】https://sifted.eu/articles/ai-biotech-cellvoyant-raise
Views: 1